Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Francesca Bruce

Senior Writer

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.

Latest From Francesca Bruce

Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups

The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.

Europe Germany

Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment

Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.

Europe Germany

Canadian Court Upholds New Drug Price Comparison Basket – With Caveats

A Canadian court has dismissed an appeal brought by industry challenging new pricing rules that introduce a revised basket of reference countries as part of cost-containment measures.

North America Canada

Canada’s Controversial Pricing Guidelines Suspended

The implementation of new pricing guidelines that are unpopular with the pharmaceutical has been put on hold, to the relief of the pharmaceutical industry.

North America Canada

European Payers Target Marketing Exclusivity For Orphan Regulation Reform

European payers are calling for changes to the EU’s orphan drug rules that would transform the incentives system and avoid the market distortions enabled by the current legislation.

Europe Health Technology Assessment

UK Planning To Raise Industry Repayments Under Statutory Pricing Scheme

The UK government says that payments need to rise if the stability of the statutory and voluntary drug pricing schemes is to be ensured.

Europe United Kingdom
See All